(Q38246241)

31 August 2017

Myeloma bone disease: pathogenesis, current treatments and future targets (English)

1 reference

31 August 2017

1 reference

Rebecca E Walker

1

1 reference

31 August 2017

Michelle A Lawson

2

1 reference

31 August 2017

Clive H Buckle

3

1 reference

31 August 2017

John A Snowden

4

1 reference

31 August 2017

Andrew D Chantry

5

1 reference

31 August 2017

1 September 2014

1 reference

31 August 2017

British Medical Bulletin

1 reference

31 August 2017

111

1 reference

31 August 2017

1

1 reference

31 August 2017

117-138

1 reference

31 August 2017

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Treatment of newly diagnosed myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Recent major improvement in long-term survival of younger patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Multiple myeloma: causes and consequences of delay in diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

New insights into the pathophysiology and management of bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Effect of pathologic fractures on survival in multiple myeloma patients: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Evidence for the secretion of an osteoclast stimulating factor in myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Myeloma bone disease: pathophysiology and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Osteoblastic cells regulate the haematopoietic stem cell niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Identification of the haematopoietic stem cell niche and control of the niche size

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Adhesion molecules--The lifelines of multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Functions of RANKL/RANK/OPG in bone modeling and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Serum levels of total-RANKL in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Treatment strategies for bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Osteoblast function in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

TNF-alpha's effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Chemokines in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Mechanisms of Wnt signaling in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Wnt proteins are lipid-modified and can act as stem cell growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Wnt signalling in stem cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Wnt signaling in osteoblasts and bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Functional and structural diversity of the human Dickkopf gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Update on Wnt signaling in bone cell biology and bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

High bone density due to a mutation in LDL-receptor-related protein 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

RANKL expression is related to the differentiation state of human osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Secreted antagonists of the Wnt signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

FrzB-2: a human secreted frizzled-related protein with a potential role in chondrocyte apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides: part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Osteoporosis: now and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Wise, a context-dependent activator and inhibitor of Wnt signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Signaling cross-talk between TGF-beta/BMP and other pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Tgf-Beta signaling in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Signaling of transforming growth factor-beta family members through Smad proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

The activin A-follistatin system: potent regulator of human extracellular matrix mineralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Sotatercept in patients with osteolytic lesions of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Activin A is an essential cofactor for osteoclast induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Guidelines for supportive care in multiple myeloma 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Development of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Podocyte injury associated glomerulopathies induced by pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Renal Failure with the Use of Zoledronic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Atypical metatarsal fracture in a patient on long term bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Zoledronic acid in myeloma: MRC Myeloma IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

BTK inhibition in myeloma: targeting the seed and the soil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

153Sm: its use in multiple myeloma and report of a clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDU016

21 January 2018

Identifiers

DOI

10.1093/BMB/LDU016

1 reference

31 August 2017

1 reference